Proton therapy training offered

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

Students at Ivy Tech Community College-Bloomington will be the first in the nation to be offered a specialized training program in proton therapy.

BLOOMINGTON, Indiana-Students at Ivy Tech Community College-Bloomington will be the first in the nation to be offered a specialized training program in proton therapy. The college has formed a partnership with ProCure Treatment Centers, Inc. to develop a certificate program that will train and credential students enrolled in the College’s Radiation Therapy program, with courses beginning next fall.

Everything but the protons


Procure’s Training and Development Center, located in Bloomington, celebrated its grand opening on March 27. The 20,000-square-foot center is the first facility in the world dedicated to proton therapy training, ProCure said in a media release. The facility offers before-the-job training that simulates all aspects of proton therapy in a replica of a proton therapy treatment center featuring everything but the actual protons.

Headquartered in Bloomington, ProCure Treatment Centers, Inc. was founded in 2005 by John Cameron, PhD, a particle therapy physics pioneer who was pivotal in the development of the Midwest Proton Therapy Institute in Bloomington. ProCure provides management support and a model for the complete design, construction, operation, and maintenance of proton centers.

Related Videos
A panel of 5 experts on colorectal cancer
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
A panel of 5 experts on colorectal cancer
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Related Content